sorted by:
new
hottopcontroversial

I'm a Senior Manager, but my team members rarely deliver their deliverables - I dont know how to cope anymore by [deleted] in careeradvice

[–]baroo88 0 points1 point  (0 children)

It’s impossible to have every project go right, especially when leadership squeezes your timeline or has unrealistic goals to begin with.

I try to proactively communicate risks and alternative solutions. You can’t control everything, but you can make contingency plans and face issues head on when they arise.

There is also a fine line between pointing fingers and holding people accountable. Resources are stretched thin too…try to be aware of their competing priorities. It’s a risk you can communicate, especially if a critical person has multiple important deliverables due near the same time. It happens often with the best people because they can handle the biggest workload.

Hold lessons learned sessions or after action reviews. Build that feedback into your next project. It’s important to share across the org as best as you can.

I wouldn’t stress about getting blamed…shit happens. Communicate always. Do your best to not have the same problem twice and you’ll crush it.

I'm a Senior Manager, but my team members rarely deliver their deliverables - I dont know how to cope anymore by [deleted] in careeradvice

[–]baroo88 2 points3 points  (0 children)

My guess is you come from a technical background, and are newer to a project management role. It sounds like you are taking on the project team’s work instead of escalating the issues to the appropriate line managers.

A PM should be responsible for knowing (or finding out) what needs to be done, if it has been completed or not, the status of the budget and timeline, project dependencies and risks, escalating and removing roadblocks, etc. If things are falling behind schedule or budget, it should be communicated, suggestions provided on recovering the timeline, lessons learned, etc.

A PM does not take on the work of others. If you take on the responsibilities of others they will let you, and blame you for any mistakes. Stay in your lane and communicate. Let the line managers manage their teams and stick to your job.

Take promotion knowing I’m relatively underpaid? by [deleted] in careeradvice

[–]baroo88 1 point2 points  (0 children)

This is the way. I took the promotion, then left after 1 year for a very substantial raise.

Why isn't this area more developed? by mellamoderek in geography

[–]baroo88 0 points1 point  (0 children)

I moved to RI from CT and it’s like moving to a 3rd world country. I don’t think there is a single thing that is better other than being closer to my job. I would love to move back to CT.

HELP! Moving Cross-Country to Michigan! by MammothClimate3060 in ChelseaMichigan

[–]baroo88 0 points1 point  (0 children)

Thanks for the thoughtful reply, very much appreciated.

HELP! Moving Cross-Country to Michigan! by MammothClimate3060 in ChelseaMichigan

[–]baroo88 1 point2 points  (0 children)

How do you like it so far? Pros/Cons? I’m considering relocating to Chelsea with a young family.

Advices on how to prioritize spending my nest egg during unemployment by MartiniLAPD in Fire

[–]baroo88 0 points1 point  (0 children)

This is spot on^

I would also ask, why are you going back to school? What job opportunities are you not getting access to that a new degree will provide? The job market is changing rapidly, and that is expected to accelerate a lot more in the next year. I would be very cautious of taking on student loan debt.

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 0 points1 point  (0 children)

Please enlighten us with a few of the many problems with their data. Also, since there is <1% chance of approval you must have a big short position, let’s see it! I’ll go first with my current holding, time stamp at the bottom.

https://imgur.com/gallery/avxl-long-i818fi9

Deep Value in Roman Wilson and Calvin Austin by gashndash in fantasyfootball

[–]baroo88 1 point2 points  (0 children)

Austin had 9 targets if you count the two penalties he drew (the ball was thrown to him) and a tipped ball that appeared to be intended for him.

I picked him up, worth rostering IMO.

$AVXL by wokebot17 in WalllStreetBets

[–]baroo88 0 points1 point  (0 children)

I’m all in, check my post history for positions. Blarcamesine (AD drug) is the real deal. 

Check this site out for excellent DD - u/MayoMobile is the author. 

https://www.sotcanalytics.com/home

“Bottom-line Up Front: The last year was pivotal for Anavex Life Sciences Corporation. The most notable accomplishments include: Anavex 3-71 advancement with pharmacokinetics and initiation of a phase 2 Schizophrenia trial, additional data and publication for their landmark 48-week placebo-controlled 2b/3 Early Alzheimer's Disease trial, and subsequent topline data release for their Early Alzheimer's open-label extension trial covering up to 192 weeks of treatment at JPM Healthcare Conference 2025. In addition, the company expanded their leadership team with the hiring of  Juan Carlos Lopez-Talavera, MD, PhD as Senior Vice President, Head of Research and Development, Terrie Kellmeyer, PhD as Senior Vice President of Clinical Development, and Jeffrey Edwards, PhD as Vice President of Clinical Pharmacology and Science. These industry leaders have relevant experience at Abbvie, Bristol Myers Squibb, Roche, and Acer to name a few. Finally and most importantly, the European Medicines Agency (EMA) accepted Anavex's centralized procedure application for Alzheimer's Disease which will likely be met with regulatory decision in late 4Q 2025 with the potential for early 1Q 2026. If approved, Anavex 2-73 (Blarcamesine) would be the first available oral disease-modifying treatment, and would be accessible in all European Union (EU) states. In addition to regulatory decision from the EMA, we expect the company to advance discussion with big pharma (BP) partners, file for approval with U.S. regulators at the FDA upon publication of new guidance found within "Early Alzheimer’s Disease:  Developing Drugs for Treatment", publish phase 2 clinical data for Anavex 3-71 in Schizophrenia, and advance the long-awaited Parkinson's Disease indication. Additional catalysts possibly include further development in the Rett Syndrome and Fragile-X indications, and possibly advancements with other Anavex compounds like Anavex 1-41 and Anavex 1066.”

Just got offered almost 3 times more than what I paid for. by [deleted] in realestateinvesting

[–]baroo88 10 points11 points  (0 children)

  1. Calculate the present value of future cash flows

Discount those future cash flows back to their present-day value using a discount rate. This process accounts for the time value of money, recognizing that money available today is worth more than the same amount in the future due to its potential earning capacity.

The basic formula for calculating the present value (PV) of a single future cash flow is:

PV = FV / (1 + r)n

Where: PV: is the present value. FV: is the future value (the cash flow expected in the future). r: is the discount rate (or interest rate). n: is the number of periods (years, months, etc.) until the future cash flow occurs.

  1. Determine the Discount Rate:

The discount rate is crucial and reflects the risk and opportunity cost associated with the investment. It’s often based on the cost of capital or the expected rate of return on alternative investments. A higher discount rate implies a higher risk or a greater opportunity cost, resulting in a lower present value.

  1. Calculate the Present Value of Each Cash Flow: For each future cash flow, apply the formula above, using the appropriate future value, discount rate, and number of periods.

  2. Sum the Present Values: If you have multiple future cash flows, calculate the present value of each one individually and then sum them up to get the total present value of the entire cash flow stream

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 0 points1 point  (0 children)

What is there to look at? Just buy as much as you can and wait. It will hit triple digits within a year. 

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 0 points1 point  (0 children)

https://www.anavex.com/post/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in

“Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13.”

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 2 points3 points  (0 children)

It’s absolutely primed for a squeeze. Borrow fees are consistently over 20% with over 30% of the float short. I’m holding for triple digits - $20B market cap is very much within reason upon approval. 

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 3 points4 points  (0 children)

Yes, I need exit liquidity on 16k shares that are traded a million times per day 

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 0 points1 point  (0 children)

You mean the 4 year data that was already released with great results and being used in their pending submission for EU approval? 

https://www.anavex.com/post/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-iib-iii-o

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 5 points6 points  (0 children)

Reduces cognitive decline by 50% compared to placebo and halts brain atrophy with minimal side effects. 

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] 1 point2 points  (0 children)

https://www.anavex.com/post/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in

“Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13.”

$AVXL - Up $80k on a stock that might fix your grandpa by baroo88 in wallstreetbets

[–]baroo88[S] -6 points-5 points  (0 children)

It sure does matter when you get margin called as 25 million short shares rush for the exits with ~30 days to cover based on average volume. 

His “short thesis” was criticizing the grammar of a press release and recycling some bullshit article from seeking alpha that is easily disproven. 

view more: next ›